Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases
Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy does not provide a sufficient Lp(a) reduction. For PCSK9 inhibi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/9/1271 |
| _version_ | 1797520138458628096 |
|---|---|
| author | Victoria A. Korneva Tatjana Yurjevna Kuznetsova Ulrich Julius |
| author_facet | Victoria A. Korneva Tatjana Yurjevna Kuznetsova Ulrich Julius |
| author_sort | Victoria A. Korneva |
| collection | DOAJ |
| description | Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy does not provide a sufficient Lp(a) reduction. For PCSK9 inhibitors a small reduction of Lp(a) levels could be shown, which was associated with a reduction in cardiovascular events, independently of the effect on LDL cholesterol. Another option is inclisiran, for which no outcome data are available yet. Lipoprotein apheresis acutely and in the long run decreases Lp(a) levels and effectively improves cardiovascular prognosis in high-risk patients who cannot be satisfactorily treated with drugs. New drugs inhibiting the synthesis of apolipoprotein(a) (an antisense oligonucleotide (Pelacarsen) and two siRNA drugs) are studied. Unlike LDL-cholesterol, for Lp(a) no target value has been defined up to now. This overview presents data of modern capabilities of cardiovascular risk reduction by lowering Lp(a) level. |
| first_indexed | 2024-03-10T07:52:35Z |
| format | Article |
| id | doaj.art-ba1867c09f214ca9a9705e43a919ada4 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T07:52:35Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-ba1867c09f214ca9a9705e43a919ada42023-11-22T12:09:37ZengMDPI AGBiomedicines2227-90592021-09-0199127110.3390/biomedicines9091271Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular DiseasesVictoria A. Korneva0Tatjana Yurjevna Kuznetsova1Ulrich Julius2Department of Faculty Therapy, Petrozavodsk State University, Lenin Ave. 33, 185000 Petrozavodsk, RussiaDepartment of Faculty Therapy, Petrozavodsk State University, Lenin Ave. 33, 185000 Petrozavodsk, RussiaLipidology and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, GermanyLipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy does not provide a sufficient Lp(a) reduction. For PCSK9 inhibitors a small reduction of Lp(a) levels could be shown, which was associated with a reduction in cardiovascular events, independently of the effect on LDL cholesterol. Another option is inclisiran, for which no outcome data are available yet. Lipoprotein apheresis acutely and in the long run decreases Lp(a) levels and effectively improves cardiovascular prognosis in high-risk patients who cannot be satisfactorily treated with drugs. New drugs inhibiting the synthesis of apolipoprotein(a) (an antisense oligonucleotide (Pelacarsen) and two siRNA drugs) are studied. Unlike LDL-cholesterol, for Lp(a) no target value has been defined up to now. This overview presents data of modern capabilities of cardiovascular risk reduction by lowering Lp(a) level.https://www.mdpi.com/2227-9059/9/9/1271lipoprotein(a)proprotein convertase subtilisin/kexin type 9 inhibitorsinclisiranlipoprotein apheresisinhibitors of apolipoprotein(a) synthesiscardiovascular risk |
| spellingShingle | Victoria A. Korneva Tatjana Yurjevna Kuznetsova Ulrich Julius Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases Biomedicines lipoprotein(a) proprotein convertase subtilisin/kexin type 9 inhibitors inclisiran lipoprotein apheresis inhibitors of apolipoprotein(a) synthesis cardiovascular risk |
| title | Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases |
| title_full | Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases |
| title_fullStr | Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases |
| title_full_unstemmed | Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases |
| title_short | Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases |
| title_sort | modern approaches to lower lipoprotein a concentrations and consequences for cardiovascular diseases |
| topic | lipoprotein(a) proprotein convertase subtilisin/kexin type 9 inhibitors inclisiran lipoprotein apheresis inhibitors of apolipoprotein(a) synthesis cardiovascular risk |
| url | https://www.mdpi.com/2227-9059/9/9/1271 |
| work_keys_str_mv | AT victoriaakorneva modernapproachestolowerlipoproteinaconcentrationsandconsequencesforcardiovasculardiseases AT tatjanayurjevnakuznetsova modernapproachestolowerlipoproteinaconcentrationsandconsequencesforcardiovasculardiseases AT ulrichjulius modernapproachestolowerlipoproteinaconcentrationsandconsequencesforcardiovasculardiseases |